Login

Willkomen zurück, bitte gebe deine Zugangsdaten ein!

Passwort vergessen

Anmeldung erfolgt in Kürze...
Fleebs-Logo
Details werden geladen...

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis | The Manila Times

Normalization of free light chains occurred by day 15 across all doses

Ähnliche Seiten

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/immuneering-reports-173-months-median-overall-survival-in-first-line-metastatic-pancreatic-cancer-patients-treated-with-atebimetinib-plus-chemotherapy/2349698

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy | The Manila Times

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/immuneering-reports-173-months-median-overall-survival-in-first-line-metastatic-pancreatic-cancer-patients-treated-with-atebimetinib-plus-chemotherapy/2349698
https://www.manilatimes.net/2026/05/21/tmt-newswire/globenewswire/dp-world-partners-with-isn-to-advance-contractor-management-and-support-operational-growth-across-canada/2348608

DP World Partners With ISN® to Advance Contractor Management and Support Operational Growth Across Canada | The Manila Times

https://www.manilatimes.net/2026/05/21/tmt-newswire/globenewswire/dp-world-partners-with-isn-to-advance-contractor-management-and-support-operational-growth-across-canada/2348608
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/new-psmaddition-data-show-58-lower-risk-of-psa-progression-with-pluvicto-in-metastatic-hormone-sensitive-prostate-cancer/2345762

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer | The Manila Times

https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/new-psmaddition-data-show-58-lower-risk-of-psa-progression-with-pluvicto-in-metastatic-hormone-sensitive-prostate-cancer/2345762
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/stop-shop-boosts-affordability-with-lower-everyday-prices-on-thousands-of-items-at-all-stores-in-new-york-and-new-jersey/2346166

Stop & Shop Boosts Affordability with Lower Everyday Prices on Thousands of Items at All Stores in New York and New Jersey | The Manila Times

https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/stop-shop-boosts-affordability-with-lower-everyday-prices-on-thousands-of-items-at-all-stores-in-new-york-and-new-jersey/2346166
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated-three-year-overall-survival-and-deep-responses-driven-by-tgf-inhibition-in-1l-rm-hpv-negative-hnscc/2349694

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC | The Manila Times

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated-three-year-overall-survival-and-deep-responses-driven-by-tgf-inhibition-in-1l-rm-hpv-negative-hnscc/2349694
https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/relay-therapeutics-announces-initial-clinical-data-demonstrating-that-zovegalisib-has-potential-for-differentiated-safety-and-efficacy-in-patients-with-pik3ca-driven-vascular-anomalies/2346924

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies | The Manila...

https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/relay-therapeutics-announces-initial-clinical-data-demonstrating-that-zovegalisib-has-potential-for-differentiated-safety-and-efficacy-in-patients-with-pik3ca-driven-vascular-anomalies/2346924